// App-Quantinova.ai

: Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Researchers

Presenter

  • Carlo Finelli

Principal Investigators

  • Matilde Y Follo

  • Sarah Parisi

  • Miriam Fogli

  • Sara Mongiorgi

  • Isabella Capodanno

  • Costanza Bosi

  • Barbara Castagnari

  • Anna Candoni

  • Monica Crugnola

  • Maria Benedetta Giannini

  • Marco Gobbi

  • Giovanna Leonardi

  • Gian Matteo Rigolin

  • Domenico Russo

  • Patrizia Tosi

  • Andrea Pellagatti

  • Jacqueline Boultwood

  • Lucio Cocco

  • Michele Cavo

Medical Centers

  • Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L. and A. Sera gnoli , University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy

  • Hematology, S.Salvatore Hospital, Pesaro, Italy

  • Department of Biomedical and Neuromotorial Sciences, Alma Mater University, Bologna, Italy

  • DIMES - Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology, University of Bologna, Bologna, Italy

  • Haematology Department,Arcispedale Santa Maria Nuova - IRCCS Reggio, Reggio emilia,Italy

  • Guglielmo da Saliceto Hospital, Piacenza, Italy

  • Hematology, Ospedale Santa Maria delle Croci, Ravenna, Italy

  • Division of Hematology and Bone Marrow Transplantation,Azienda Sanitaria-Universitaria Integrata, University of Udine,Udine,Italy

  • Department of Medicine and Surgery, University of Salerno, Salerno, Italy

  • Oncology, I.R.S.T., Meldola (FC), Italy

  • Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy

  • Hematology section, Department of Medical Sciences, University of Ferrara - Azienda Ospedaliera-Universitaria di Ferrara, University of Ferrara, Ferrara, Italy

  • Bone Marrow Transplant Unit, ASST-Spedali Civili di Brescia, Dpt of Clinical and Experimental Sciences, University of Brescia, Pavia, Pavia, Italy

  • Hematology Unit, Infermi Hospital Rimini, Rimini, Italy

  • Bloodwise Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

  • Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, "S. Orsola-Malpighi" Hospital, Bologna, Italy

Locations

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Lenalidomide

  • Vidaza

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved